Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an alternative to nintedanib and enabling combination therapy. The introduction of new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results